Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Notice to readers: Newly licensed smallpox vaccine to replace old smallpox vaccine

Filetype[HTM]


Select to view the document on External site.
This document file type cannot be previewed
English
Details You May Also Like

Details:

  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    CDC has begun distribution of a new-generation smallpox vaccine, ACAM2000 (Acambis, Inc., Cambridge, Massachusetts), to civilian laboratory personnel, the military, and state public health preparedness programs. ACAM2000 is a live, vaccinia virus smallpox vaccine that was licensed for use in the United States by the Food and Drug Administration in August 2007 (1).* ACAM2000 will be replacing Dryvax smallpox vaccine (Wyeth Pharmaceuticals, Inc., Marietta, Pennsylvania) because of withdrawal of the Dryvax license. ACAM2000 is a live vaccinia virus derived from plaque purification cloning from Dryvax. The safety data available from the ACAM2000 clinical trials indicate a similar safety profile to Dryvax.
  • Subjects:
  • Document Type:
    Journal Issue
  • Place as Subject:
    United States
  • Collection(s):
  • Main Document Checksum:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov